$1.35
+0.01 (+0.75%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ALLR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 1 observational · 2 with posted results
Held by 5 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, TWO SIGMA INVESTMENTS, LP, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 2.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Clinical Pre-screening Protocol for Ovarian CancerNCT03877796observationalIdentification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug | — | Recruiting | Device: Drug Response Predictor® (DRP) | Ovarian Cancer | 60 | Jun 2027 | ≤ 315 d | 2026-07-30 |
| Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian CancerNCT03878849Evaluate the optimal dose of 2X-121 as single agent therapyRandomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: 2X-121, 2X-121 | Advanced Ovarian Cancer | 40 | Mar 2027 | ≤ 224 d | 2025-08-28 |
| Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.NCT04796324results2026-03-12Clinical Benefit Rate (CBR)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Company Decision | Drug: Ixabepilone Injection | Metastatic Breast Cancer | 13 | 2024-12-01actual | — | 2026-03-12 |
| Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRPNCT03562832Anti-tumour efficacy after treatment with 600 mg 2X-121 as single oral agent in a 21-days cycle in mBC patients selected by the 2X-121 DRPOpen-label · Treatment | Phase 2 | Completed | Drug: PARP inhibitor 2X-121 | Metastatic Breast Cancer | 20 | 2024-04-01actual | — | 2025-01-23 |
| Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid TumorsNCT05571969results2026-06-01Determination of the MTD of 2X-121 Monotherapy (Number of Subjects With Dose-Limiting Toxicities)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ · Informed Consent Form ↗ | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision. | Drug: 2X-121 600 mg, 2X-121 800 mg, 2X-121 1000 mg · Combination product: 2X-121 + 300 mg dovitinib, 2X-121 + 400 mg dovitinib, 2X-121 + 500 mg dovitinib | Advanced Solid Tumors | 14 | 2024-02-19actual | — | 2026-06-01 |
| Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory TumoursNCT01861496Maximum tolerated dose (MTD) and recommended dose (RD) by evaluating the safety and tolerabilityOpen-label · Treatment | Phase 1/2 | Completed | Drug: LiPlaCis | Phase 1: Advanced or Refractory Solid Tumours, Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer | 50 | Oct 2021actual | — | 2022-02-24 |
| Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)NCT03643107Anti-tumor effect of Irofulven with prednisoloneOpen-label · Treatment | Phase 2 | Completed | Drug: Irofulven · Combination product: Prednisolone 10 mg | Metastatic Castration-Resistant Prostate Cancer Patients | 15 | 2021-10-01actual | — | 2025-01-23 |
| Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRPNCT03196947Maximum Tolerated DosageOpen-label · Treatment | Phase 1/2 | Terminatedsponsor's stated reason: The study was terminated early due to sponsors decision | Drug: APO010 | Relapsed/Refractory Multiple Myeloma | 1 | 2020-01-16actual | — | 2020-01-30 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19